Showing posts with label Hemophilia Market. Show all posts
Showing posts with label Hemophilia Market. Show all posts

Monday, 12 June 2017

Global Hemophilia Industry Key Trends, Size, Growth, Shares And Forecast Research Report 2015

Researchmoz added Most up-to-date research on "Global Hemophilia Market Report: 2015 Edition" to its huge collection of research reports.

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=281630

The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.

The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Table of Content

1. Overview

2. Market Analysis
2.1 Global Hemophilia Market

- Market Value
- Market Segmentation

2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A

- Market Value
- Patients Treated
- Regional Breakdown
- Supply/Demand of Factor VIII

2.2.2 Hemophilia B

- Market Value
- Patients Treated

2.2.3 Hemophilia A & B with Inhibitors

- Market Value

2.2.4 Von Willebrand Disease

- Market Value

2.3 Regional Analysis
2.3.1 The US

- Market Size
- Patients Treated
- Hemophilia Prevalence

2.3.2 Australia

- Market Overview
- Market Share

2.3.3 Europe

- Market Size
- Patients Treated

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Increased Rate of Diagnosis and Treatment
3.1.2 Rising Male Population
3.1.3 Rising Global Healthcare Expense
3.1.4 FDA Regulation and Patents
3.2 Key Trends
3.2.1 Introduction of New Products
3.2.2 Increased Competition in rFVIII Market
3.2.3 Adoption of Prophylactic Treatment
3.3 Challenges
3.3.1 High Risk and Cost Associated with New Drugs
3.3.2 Rising Cost of Hemophilia Treatment
3.3.3 Low Switching Rate among Patients
3.4 Significant Developments
3.4.1 Next-Generation Long-Acting Factor VIII in Process
3.4.2 Ready-To -Use Product by Novo Nordisk

4. Competitive Landscape
4.1 Global

- Market Share
- Products in Development

4.2 The US

- Leading Products

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=281630

Wednesday, 19 April 2017

Global Hemophilia Industry Key Trends, Size, Growth, Shares And Forecast Research Analysis & Outlook (2017-2021)

Researchmoz added Most up-to-date research on "Global Hemophilia Market: Industry Analysis & Outlook (2017-2021)" to its huge collection of research reports.

The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.

Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.

The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer’s reluctance in switching to new therapy
options.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1064504

The report offers an in-depth analysis of the global hemophilia market. It also covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.

Table of Content

1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis & Treatment

2. Global Market Analysis
2.1 Global Hemophilia Market by Value
2.2 Global Hemophilia Market Forecast by Value
2.3 Global Hemophilia Market by Therapeutic Class
2.3.1 Global Hemophilia Traditional Factors Market Forecast by Value
2.4 Global Hemophilia Market by Type
2.4.1 Global Hemophilia A Market Forecast by Value
2.4.2 Global Hemophilia A Market Forecast by Therapeutic Class
2.4.3 Global Hemophilia A Market by Severity
2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
2.4.5 Global Hemophilia B Market Forecast by Value
2.4.6 Global Hemophilia B Market Forecast by Therapeutic Class
2.4.7 Global Hemophilia B Market by Severity

3. Regional Market Analysis
3.1 The US
3.1.1 The US Hemophilia Market by Value
3.1.2 The US Hemophilia Market Forecast by Value
3.1.3 The US Hemophilia Market by Type
3.1.4 The US Hemophilia A Market Forecast by Value
3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
3.1.6 The US Hemophilia A Market-Pediatric Patients Volume Forecast
3.1.7 The US Hemophilia A Market- Adult Patients Volume Forecast
3.1.8 The US Hemophilia B Market Forecast by Value
3.1.9 The US Hemophilia B Market-Treated Patient Volume Forecast
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
4.1.2 Growing Market for FVIII
4.1.3 Increasing Diagnosis Rate
4.1.4 Increasing Healthcare Expenditure
4.2 Key Trends
4.2.1 Development of Novel Hemophilia Treatments
4.2.2 Subcutaneous Dosing
4.2.3 Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
4.2.4 Popularity of Gene Therapy
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape
5.1 Global Hemophilia Market
5.1.1 Revenue and Market Cap Comparison
5.2 Global Hemophilia A Market
5.2.1 Market Share
5.2.2 Factor VIII Products Market Share
5.2.3 Factor VIII Gene Therapy Market Share Forecast
5.3 Global Hemophilia B Market
5.3.1 Market Share
5.3.2 Factor IX Products Market Share Forecast
5.3.3 Factor IX Gene Therapy Market Share Forecast

6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Bayer Group
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Shire PLC
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novo Nordisk
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1064504

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...